Optimal regimen proposed for treating HIV and TB in coinfected individuals

摘要

Recent findings presented at the XVII International AIDS Conference (Vienna, 18-23 July) may help to optimize the treatment of severely immunosuppressed individuals coinfected with TB and HIV. The Phase III Cambodian Early versus Late Introduction of Antiretroviral Drugs (CAMELIA) trial, launched in 2006, followed 661 Cambodian volunteers with newly diagnosed HIV-TB coinfection aged 18 years or older for 50 weeks. TB is one of the leading causes of death in HIV-infected persons and approximately 30% of HIV-infected persons are estimated to have latent TB infection. In immuno-compromised individuals, the risk of developing TB is estimated to approach 10-20% per year and the inevitable overlap between the two diseases means that there is a pressing need to determine treatment regimens for coinfected individuals.